WO2012077968A2 - Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof - Google Patents

Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof Download PDF

Info

Publication number
WO2012077968A2
WO2012077968A2 PCT/KR2011/009413 KR2011009413W WO2012077968A2 WO 2012077968 A2 WO2012077968 A2 WO 2012077968A2 KR 2011009413 W KR2011009413 W KR 2011009413W WO 2012077968 A2 WO2012077968 A2 WO 2012077968A2
Authority
WO
WIPO (PCT)
Prior art keywords
valsartan
lercanidipine hydrochloride
granules
composition according
lercanidipine
Prior art date
Application number
PCT/KR2011/009413
Other languages
English (en)
French (fr)
Other versions
WO2012077968A3 (en
Inventor
Young Sik Chung
Soo Ah Park
Ree Sun Kim
Sung Il Kim
Jae Hyeon Juhn
Dong Kyu Kim
Yoo Rin Kim
Hee Dong Park
Seong Jae Park
Sung Hack Lee
Ju Hyun Kim
Min Young Jung
Original Assignee
Lg Life Sciences Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46207595&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2012077968(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to SG2013038211A priority Critical patent/SG190326A1/en
Priority to PH1/2013/500980A priority patent/PH12013500980A1/en
Priority to CN201180058951.9A priority patent/CN103249415B/zh
Priority to EP11847739.7A priority patent/EP2648730A4/en
Priority to UAA201307936A priority patent/UA108277C2/ru
Application filed by Lg Life Sciences Ltd. filed Critical Lg Life Sciences Ltd.
Priority to BR112013013415A priority patent/BR112013013415A2/pt
Priority to EA201390844A priority patent/EA201390844A1/ru
Priority to AU2011339150A priority patent/AU2011339150B2/en
Priority to MX2013005716A priority patent/MX2013005716A/es
Publication of WO2012077968A2 publication Critical patent/WO2012077968A2/en
Publication of WO2012077968A3 publication Critical patent/WO2012077968A3/en
Priority to TNP2013000212A priority patent/TN2013000212A1/fr
Priority to IL226449A priority patent/IL226449A0/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising lercanidipine hydrochloride and valsartan as active components and method for the preparation thereof.
  • Hypertension is a most common cardiovascular disease. Persistent hypertension damages blood vessels in the kidneys, heart and brain, which increases the occurrence of renal failure, coronary-artery diseases, heart failure and stroke. Hypertension is divided into two types ⁇ i.e., essential or primary hypertension and secondary hypertension. Essential hypertension, the cause of which is unknown, occurs without a specific underlying disease. Most (95%) of hypertensive patients, especially those over the age of 40, belong to this type. Even though the cause of essential hypertension cannot be found since there is no underlying disease, problematic issues may be genetics, dietary habit of eating salty food, obesity, old age, stress, heavy smoking and drinking. Secondary hypertension comes from a specific causative disease. About 5% of hypertensive patients, relatively young people, belong to this type. Secondary hypertension is caused by nephritis, endocrine disruption and toxemia during pregnancy, etc., and blood pressure goes down with treatment of the causative diseases.
  • Antihypertensive treatment is not for the causative disease and depends on blocking the normal physiological mechanism of blood pressure regulation. Antihypertensive treatment is performed on subclinical patients, and it does not affect directly the inconvenience of the patients but prevents the symptom and death from occurring in the future by lowering blood pressure.
  • Antihypertensive agents are generally classified according to their regulation site and mechanism of action into three categories: diuretics, sympatholytic agents and vasodilators, which are subdivided according to their active sites.
  • Diuretics which act to increase the amount of urine to excrete water and salts from the body, lower blood pressure by reducing water and salts in the body.
  • a sympathetic nerve acts to increase the frequency and intensity of the heartbeat and to constrict blood vessels.
  • Sympatholytic agents suppress the action of the sympathetic nerve to lower blood pressure.
  • Vasodilators lower blood pressure by dilating blood vessels.
  • Various vasodilators are known such as ACE inhibitors which inhibit the synthesis of angiotensin II, a vasoconstrictor, and angiotensin II receptor blockers which inhibit the action of angiotensin II.
  • a calcium channel blocker which inhibits the inflow of calcium into cells to lower blood pressure, is also a vasodilator since high concentration of intracellular calcium results in vasoconstriction to raise blood pressure.
  • the dose of the antihypertensive agent is generally increased.
  • an excessively increased dose may cause adverse effects.
  • the combined use of medicines having different mechanisms of action, rather than the increased use of a medicine can minimize adverse effects while obtaining sufficient effect.
  • the antihypertensive effect increases synergistically by the concurrent action of medicines having different mechanisms of action. Furthermore, a homeostasis compensatory action of a medicine is suppressed by another medicine, so that more effective antihypertensive action is obtained. For example, reflexive tachycardia and retention of salt and water, which are caused by the use of vasodilators, may be adjusted by the use of ⁇ -blockers and diuretics, respectively, so that the antihypertensive effect increases.
  • hypertension is nearly asymptomatic and must be regulated for life, so patient compliance with the medicine determines the outcome of the treatment.
  • the combined use of effective medicines having low adverse effect can improve the quality of life and increase patient compliance.
  • complex formulations containing at least two medicines in one pill are commercially available. They are cheap and easy to take. Use of the complex formulations can increase patient compliance and prevent or delay damage of the target organ caused by hypertension.
  • the present inventors have conducted intensive research to develop a new pharmaceutical composition by the combined use of at least two antihypertensive agents having different mechanisms of action for increasing the hypertensive effect synergistically, reducing adverse effects and improving patient compliance.
  • the present inventors have found that such purposes can be achieved by the combined use of lercanidipine hydrochloride and valsartan, especially by the specific complex formulation comprising them, and thus completed the present invention.
  • the object of the present invention is to provide a pharmaceutical composition for the prevention and treatment of cardiovascular diseases which comprises as active components lercanidipine hydrochloride and valsartan having different mechanisms of action.
  • the present invention provides a complex formulation comprising lercanidipine hydrochloride and valsartan in a separated form.
  • Another object of the present invention is to provide a method for preparation of the complex formulation for the prevention and treatment of cardiovascular diseases which comprises as active components lercanidipine hydrochloride and valsartan.
  • Lercanidipine hydrochloride is a dihydropyridine calcium antagonist and, like other calcium antagonists, inhibits calcium inflow into arterial smooth muscle to relax peripheral arterioles and reduce the blood pressure. Lercanidipine does not cause negative myocardial contraction but results in slight reflex tachycardia. Lercanidipine has a strong affinity to the dihydropyridine subunit of L-type calcium channel and competitively antagonizes thereto. Calcium channel antagonists are considered safe and are proven to be effective on all types of hypertension. Lercanidipine is a new kind of dihydropyridine calcium antagonist and has proven to have a strong and long-acting hypotensive effect in pre-clinical trials.
  • Lercanidipine is favorably tolerable in a dose of 30 mg or lower and reduces blood pressure in a dose-dependent manner.
  • Calcium antagonists are considered renal-protective due to their antihypertensive effect. This potential is proven in the renal failure and nephrotoxicity induced by chemotherapy, contrast media, cyclosporins or aminoglycoside antibiotics. In addition, calcium antagonists have a renal-protective effect on the kidneys of donors in kidney transplants.
  • Lercanidipine is typically used in a dose of 10 to 20 mg once a day and the maximum dose is about 30 mg per day. Lercanidipine is rapidly absorbed after oral administration and reaches its maximum plasma concentration in 1.5 to 3 hours after administration, which is subjected to extensive first-pass metabolism.
  • lercanidipine Absorption of lercanidipine is highly dependent on food intake and increases remarkably (3- to 4-fold) by simultaneous intake of food.
  • An oral tablet containing 10 or 20 mg of lercanidipine is commercially available under the trade name “Zanidip ® tablet.”
  • Lercanidipine, sold by Recordati S.p.A (Milan, Italy) can be manufactured according to the method disclosed in EP 0153016 and US 4705797 of which the whole context is quoted herein.
  • US-A1-2003/0180355 discloses a method of treating hypertensive patients which comprises administering a complex formulation containing lercanidipine and enalapril as active components.
  • Valsartan ((S)-N-valeryl-N- ⁇ [2’-(1H-tetrazol-5-yl)-biphenyl-4-yl]-methyl ⁇ -valine), an angiotensin II receptor antagonist, reduces blood pressure by vasodilation.
  • Angiotensin II has a vasoconstriction and sodium retention effect.
  • Valsartan is commercially available (Tareg ® tablet) and also manufactured by a known method. For example, the preparation of valsartan is disclosed in US 5399578 of which the whole context is quoted herein. Valsartan is used for the purpose of the present invention in its isolated form or a suitable salt form.
  • valsartan In the U.S., valsartan is used in an initial dose of 80 to 160 mg qd and the maximum dose is 320 mg qd. In Korea, valsartan is prescribed for patients with cardiac insufficiency or postmyocardial infarction syndrome in a dose of 160 mg b.i.d. However, if the blood pressure of the patient does not reach the desired value with the dose of 160 mg b.i.d, valsartan is replaced with other drugs. Valsartan is typically used in a dose of about 40 to 320 mg, preferably about 80 to 320 mg, most preferably about 80 to 160 mg in a tablet.
  • the present inventors have conducted various experiments of lercanidipine hydrochloride and valsartan having the above-mentioned mechanisms of action and maximum daily doses to confirm that the combined use of these drugs has a synergistic effect on the prevention and treatment of cardiovascular diseases compared with that of single use, reduces the adverse effects caused by single use, and improves patient compliance. Accordingly, the pharmaceutical composition comprising lercanidipine hydrochloride and valsartan can be used effectively for the prevention and treatment of cardiovascular diseases.
  • cardiovascular diseases include angina pectoris, hypertension, arteriospasm, cardiac arrhythmia, cardiac hypertrophy, cerebral infarction, congestive heart failure, myocardial infarction, etc., but not limited thereto.
  • a complex formulation comprising lercanidipine hydrochloride and valsartan prepared by simply mixing the two drugs may have some problems caused by the difference between their inherent physical properties.
  • the first problem resides in the difference of their pKa value.
  • Lercanidipine hydrochloride has a pKa value of about 6.83 and the pKa of valsartan is about 3.92. Accordingly, lercanidipine hydrochloride has an increased solubility at pH 4.0 or lower, while valsartan has an increased solubility at pH 4.0 or higher.
  • Such a pKa difference between the two drugs affects the solubility of each drug.
  • Valsartan begins to gel at pH 4.0 or lower due to its low solubility and dissolves very slowly. Such delayed dissolution causes delayed absorption of valsartan in the small intestine.
  • gelling of valsartan can delay the dissolution of lercanidipine hydrochloride. This trouble can adversely affect the absorption of lercanidipine hydrochloride which is rapidly disintegrated and absorbed in the gastro-intestinal tract. Accordingly, gelling of valsartan at low pH in a complex formulation must be prevented.
  • the third problem is low dissolution of the complex formulation.
  • the complex formulation was prepared by wet-granulation of the mixture of lercanidipine hydrochloride and valsartan, the complex formulation showed low dissolution due to the interaction between the two components. Such low dissolution seriously affects the absorption and bioavailability of the two components. Decreased bioavailability is also expected to decrease the efficacy of the complex formulation. Therefore, an improved manufacturing process is required to prevent the problem.
  • the fourth problem is the difference of disintegration time between the commercially available single drug formulations, which makes it difficult to maintain the inherent dissolution pattern of each drug by using conventional formulation methods.
  • the present inventors have contrived a complex formulation comprising lercanidipine hydrochloride and valsartan that physically separates the two components to minimize the contact area and chance of making contact.
  • the complex formulation can provide superior dissolution rates of both lercanidipine hydrochloride and valsartan.
  • the pharmaceutical composition comprising lercanidipine hydrochloride and valsartan according to the present invention has a superior effect on the prevention and treatment of cardiovascular diseases and their complex diseases, and reduces adverse effects of each component due to the synergistic combination of the two components having different mechanisms of action.
  • the present invention provides a complex formulation comprising lercanidipine hydrochloride and valsartan in a separated form so that the problems caused by simple mixture of lercanidipine hydrochloride and valsartan may be overcome and the dissolution rates of both components may increase.
  • Figure 1 is a graph showing the results of a dissolution test of lercanidipine for the complex formulations of Examples 1 to 4 compared with that of Comparative Example 1.
  • Figure 2 is a graph showing the results of a dissolution test of lercanidipine for the complex formulations of Examples 5 to 8 compared with that of Comparative Example 1.
  • Figure 3 is a graph showing the results of a dissolution test of lercanidipine for the complex formulations of Examples 1 to 4 compared with those of Examples 9 to 12.
  • Figure 4 is a graph showing the results of a dissolution test of lercanidipine for the complex formulation of Example 1 compared with that of Example 13.
  • Figure 5 is a graph showing the results of a dissolution test of lercanidipine for the complex formulation of Example 1 compared with those for the formulations of Comparative Examples 2 and 3.
  • Figure 6 is a graph showing the change (%) of systolic blood pressure (BP) with the passage of time after the combined administration of lercanidipine hydrochloride 2 mg/kg (Z) and valsartan 16 mg/kg (V) according to Test Example 8 ( *** p ⁇ 0.001 ( vs . control), ## p ⁇ 0.01 ( vs . valsartan)).
  • Figure 7 is a graph showing the change (%) of mean BP with the passage of time after the combined administration of lercanidipine hydrochloride 2 mg/kg (Z) and valsartan 16 mg/kg (V) according to Test Example 8 ( *** p ⁇ 0.001 ( vs . control), ## p ⁇ 0.01 ( vs . valsartan)).
  • Figure 8 is a graph showing the change (%) of diastolic BP with the passage of time after the combined administration of lercanidipine hydrochloride 2 mg/kg (Z) and valsartan 16 mg/kg (V) according to Test Example 8 ( *** p ⁇ 0.001 ( vs . control), ## p ⁇ 0.01 ( vs . valsartan)).
  • Figure 9 is a graph showing the change (%) of heart rate with the passage of time after the combined administration of lercanidipine hydrochloride 2 mg/kg (Z) and valsartan 16 mg/kg (V) according to Test Example 8 ( *** p ⁇ 0.001 ( vs . control), ## p ⁇ 0.01 ( vs . valsartan)).
  • a complex formulation comprising lercanidipine hydrochloride and valsartan in a separated form is prepared by separate granulations of lercanidipine hydrochloride and valsartan.
  • a method for the preparation of the complex formulation of the present invention comprises the steps of:
  • the complex formulation of the present invention is made by preparing lercanidipine hydrochloride granules and valsartan granules separately, mixing the two granules and then pressing the mixtures into a tablet.
  • the complex formulations of Examples 1 to 4 prepared according to the above process show improved dissolution of lercanidipine hydrochloride without affecting the dissolution of valsartan compared with the complex formulation of Comparative Example 1 which is prepared by wet-granulation of an unseparated mixture of lercanidipine hydrochloride and valsartan (see Figure 1).
  • Another specified embodiment of the present invention provides a bilayer tablet of the complex formulation comprising lercanidipine hydrochloride and valsartan.
  • the bilayer tablet can be prepared by pressing the valsartan granules into a first tablet layer and then pressing the lercanidipine hydrochloride granules into a second tablet layer by using a bilayer tablet press.
  • the bilayer tablet of the present invention shows superior dissolution of lercanidipine hydrochloride like the complex formulations of Examples 1 to 4 (see Figure 2).
  • the bilayer tablet can comprise a separation layer between the lercanidipine hydrochloride layer and the valsartan layer so that a trilayer tablet may be obtained.
  • the separation layer may consist of, for example, microcrystalline cellulose.
  • a still further embodiment of the present invention provides a complex formulation comprising lercanidipine hydrochloride and valsartan in a separated form, wherein a tablet consisting of valsartan is coated with lercanidipine hydrochloride.
  • a formulation can be prepared by dissolving or dispersing lercanidipine hydrochloride and an excipient in a coating solvent to make a coating composition and coating a tablet consisting of valsartan with the coating composition.
  • the excipient include polyvinylpyrrolidone, and ethanol can be used as the coating solvent.
  • another separation layer may be placed between the valsartan tablet and the lercanidipine hydrochloride coating.
  • the complex formulation of the present invention may comprise 4 to 32 parts by weight, preferably 4 to 16 parts by weight of valsartan per 1 part by weight of lercanidipine hydrochloride. If the amount of valsartan is less than 4 parts by weight per 1 part by weight of lercanidipine hydrochloride, the desired effect cannot be obtained. On the other hand, a formulation containing more than 32 parts by weight of valsartan per 1 part by weight of lercanidipine hydrochloride is not permitted.
  • composition of the present invention for the prevention and treatment of cardiovascular diseases can comprise a pharmaceutically acceptable carrier or excipient in each of the lercanidipine hydrochloride granules and the valsartan granules.
  • pharmaceutically acceptable carrier or excipient include microcrystalline cellulose, lactose, low-substituted hydroxypropyl cellulose, disintegrating agents (e.g., croscarmellose sodium, crospovidone and sodium starch glycolate) and granulation binders (e.g., polyvinylpyrrolidone and hydroxypropyl cellulose).
  • a lubricant such as colloidal silicon dioxide, hydrous silicon dioxide, magnesium stearate, sodium stearyl fumarate (Pruv ® ), glyceryl behenate (Compritol 888 ® ), calcium stearate, stearic acid and talc may be included.
  • the lercanidipine hydrochloride granules may comprise 4 to 10 parts by weight of a pharmaceutically acceptable excipient per 1 part by weight of lercanidipine hydrochloride; and the valsartan granules may comprise 1 to 2 parts by weight of a pharmaceutically acceptable excipient per 1 part by weight of valsartan.
  • a ratio applies to all the formulations of the present invention including the separated granules. If the formulation has a ratio out of the above range, it may create tablets that are too small or too large, and its dissolution may be delayed or increased.
  • the ratio of the disintegrating agent used in the present invention is noted.
  • Conventional super-disintegrating agents such as croscarmellose sodium, crospovidone and sodium starch glycolate, are recommended to be used in an amount of 0.5 to 8.0 wt% based on the total amount of excipients. In the present invention, however, 5 to 20 wt% overdose of the super-disintegrating agents is used to prevent gelling and show inherent dissolution behavior.
  • Conventional formulations coated by using overdose of a super-disintegrating agent have a problem that coating is difficult due to rapid moisturizing and the coated layer cracks during storage. However, it is confirmed that the present invention does not have such troubles.
  • coating agents available in film coating layer include conventional ones, such as hydroxypropylmethyl cellulose, Opadry ® series, Eudragit ® series, but not limited thereto.
  • Lercanidipine hydrochloride granules and valsartan granules having the above compositions were wet-granulated using distilled water, dried and milled to 25 mesh. The two granules were mixed and compressed into complex tablets which were then film coated. Opadry ® II sold by Colorcon as PVPs was used as the film coating material, and the film coating was carried out in the same manner in all the following examples and comparative examples. The mixture was combined for a time of 5 minutes or more so that the super-integrating agent which was added in the process of wet-granulation was sufficiently wetted. Such a sufficient combination time increases porosity of the granules, which results in the facilitation of disintegration time to prevent gelation. In the following examples, all processes of wet-granulation were carried out as above.
  • Lercanidipine hydrochloride granules and valsartan granules having the above compositions were wet-granulated using distilled water, dried and milled to 25 mesh. The two groups of granules were compressed into bilayer solid forms and thus the bilayer solid forms were film coated.
  • Lercanidipine hydrochloride granules and valsartan granules having the above compositions were wet-granulated using distilled water, dried and milled to 25 mesh.
  • the valsartan granules were added to make the first tablet part, the separation layer was added to make the second tablet part, and the lercanidipine hydrochloride granules were added to make the third tablet part.
  • the complex trilayer tablet was obtained and film coated.
  • Example 13 Preparation of tablets coated with lercanidipine hydrochloride layer
  • the valsartan granules having the above composition were pressed into tablets which were then introduced into a coating machine.
  • Lercanidipine hydrochloride and polyvinylpyrrolidone were dissolved and suspended in ethanol to prepare the coating layer.
  • the valsartan tablet was coated by spraying the coating layer thereon, and then film coated.
  • Example 2 The same amounts of lercanidipine hydrochloride, valsartan and excipients as Example 1 were mixed altogether, wet-granulated and then pressed into tablets. The tablets thus obtained were film coated.
  • Comparative Example 2 Tablets obtained from simple mixture of commercially available granules
  • Granules having the same compositions as the commercially available lercanidipine hydrochloride (Zanidip ® tablet) and valsartan (Tareg ® tablet) were prepared, simply mixed and pressed into tablets and then film coated.
  • Tablets were prepared according to the same prescription and process as the commercially available lercanidipine hydrochloride (Zanidip ® tablet).
  • Test Example 1 Dissolution test of lercanidipine hydrochloride for preparations according to Examples 1 to 4
  • UV spectrophotometer (Wavelength 240 nm)
  • Test Example 2 Dissolution test of lercanidipine hydrochloride for preparations according to Examples 5 to 8
  • Test Example 3 Dissolution test of lercanidipine hydrochloride for preparations according to Examples 9 to 12
  • Example 4 Dissolution test of lercanidipine hydrochloride for preparation according to Example 13
  • Example 13 For the separated coating tablet of Example 13 and the wet complex tablet of Example 1, a dissolution test was performed and compared under the same conditions as Test Example 1.
  • Test Example 5 Comparative dissolution test for preparations according to Example 1, and Comparative Examples 2 and 3
  • Example 1 For the complex tablet of Example 1 prepared from the separated granules, the tablet of Comparative Example 2 obtained from a simple mixture of commercial granules and the commercial preparation of Comparative Example 3, a dissolution test was performed and compared under the same conditions as Test Example 1.
  • the complex tableta according to Example 1 showed the same dissolution pattern of lercanidipine hydrochloride as the commercial preparation of lercanidipine hydrochloride according to Comparative Example 3.
  • the tablet of Comparative Example 2 which was obtained by simply mixing the commercially available lercanidipine hydrochloride granules and valsartan granules and pressing them into tablets showed a very low dissolution of lercanidipine hydrochloride, which seems to be caused by the gelation of valsartan.
  • Test Example 6 Clinical effect by combination therapy of lercanidipine hydrochloride and valsartan
  • the subjects were 20- to 75-year-old patients suffering from essential hypertension, who showed the blood pressure of 90 mmHg ⁇ DBP (diastolic blood pressure) ⁇ 109 mmHg when measured in Week 0 after the administration of placebo for 2 weeks.
  • the subject patients took a placebo in a single blind during the run-in period of 2 weeks right after the drug holiday of 0 ⁇ 1 week.
  • the subjects were randomly assigned to a total of four groups consisting of one placebo group, four monotherapy groups and four combination therapy groups in the same probability, they took the drug in a double blind according to the group, measuring point and administration period in the following table.
  • the commercially available Zanidip ® tablet 10 mg was used as lercanidipine hydrochloride
  • the commercially available Tareg ® tablet 80 mg was used as valsartan.
  • the blood pressure of the subject patients was measured according to the blood pressure monitoring guidelines provided by the Korean Society of Hypertension to calculate the changes of DBP and SBP (systolic blood pressure) from the baselines after 8 weeks (values after 8 weeks - baseline).
  • DBP and SBP systolic blood pressure
  • Test Example 7 Clinical effect by combination therapy of lercanidipine hydrochloride and valsartan
  • the subjects were 20- to 75-year-old patients suffering from essential hypertension, who showed the blood pressure of 95 mmHg ⁇ DBP ⁇ 114 mmHg when measured in Week 0 after the administration of placebo for 2 ⁇ 4 weeks.
  • the subject patients took a placebo in a single blind during the run-in period of 2 ⁇ 4 weeks right after the drug holiday of 1 week.
  • the subjects were randomly assigned to a total of four groups consisting of one placebo group, two monotherapy groups and one combination therapy group in the same probability, they took the drug in a double blind according to the group, measuring point and administration period in the following table.
  • the commercially available Zanidip ® tablet 10 mg was used as lercanidipine hydrochloride
  • the commercially available Tareg ® tablet 80 mg was used as valsartan.
  • the blood pressure of the subject patients was measured according to the blood pressure monitoring guidelines provided by the Korean Society of Hypertension to calculate the changes of DBP and SBP from the baselines after 8 weeks (values after 8 weeks - baseline).
  • the effect of the combination therapy was compared with that of the monotherapy to evaluate the superiority.
  • Test Example 8 Effect from combination therapy of lercanidipine hydrochloride and valsartan in rats
  • the blood pressure and heart rate of the test animals were measured using BP-2000 Blood Pressure Analysis System (Visitech). After the measurement, the animals were fasted for about 12 hours, during which beverage was provided ad libitum.
  • the respective test drugs were orally administered to the fasted test animals in a volume of 5 ml/kg. The same volume of medium was orally administered to the negative control group.
  • the test drugs lercanidipine hydrochloride and valsartan were used after being dissolved in 20% 2-hydroxypropyl-beta-cyclodextrin (HPCD).
  • the combination therapy group administered 2 mg/kg of lercanidipine hydrochloride and 16 mg/kg of valsartan showed significant blood pressure decrease and heart rate increase in comparison with both the monotherapy group administered 16 mg/kg of valsartan and the control group 1 hour after administration in SHR.
  • the monotherapy group administered 16 mg/kg of valsartan showed no significant blood pressure decrease or heart rate increase in comparison with the control group.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/KR2011/009413 2010-12-09 2011-12-07 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof WO2012077968A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
MX2013005716A MX2013005716A (es) 2010-12-09 2011-12-07 Formulacion de un complejo que comprende clorhidrato de lercanidipina y valsartan y metodo para la preparacion de la misma.
EA201390844A EA201390844A1 (ru) 2010-12-09 2011-12-07 Комплексный состав, содержащий гидрохлорид лерканидипина и валсартан, и способ его получения
CN201180058951.9A CN103249415B (zh) 2010-12-09 2011-12-07 包含盐酸乐卡地平和缬沙坦的复合制剂及其制备方法
EP11847739.7A EP2648730A4 (en) 2010-12-09 2011-12-07 COMPLEX FORMULATION WITH LERCANIDIPIN HYDROCHLORIDE AND VALSARTAN AND METHOD FOR THE PRODUCTION THEREOF
UAA201307936A UA108277C2 (ru) 2010-12-09 2011-12-07 Комплексный препарат, содержащий лерканидипина гидрохлорид и валсартан, и способ его получения
SG2013038211A SG190326A1 (en) 2010-12-09 2011-12-07 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
BR112013013415A BR112013013415A2 (pt) 2010-12-09 2011-12-07 composição farmacêutica, e, método para a preparação de uma composição
PH1/2013/500980A PH12013500980A1 (en) 2010-12-09 2011-12-07 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
AU2011339150A AU2011339150B2 (en) 2010-12-09 2011-12-07 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
TNP2013000212A TN2013000212A1 (en) 2011-12-07 2013-05-15 Complex formulation comprising lercanidipine hydrochloride and valsartan and mathod for the preparation therof
IL226449A IL226449A0 (en) 2010-12-09 2013-05-20 A complex formulation containing larcanidipin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100125804 2010-12-09
KR10-2010-0125804 2010-12-09

Publications (2)

Publication Number Publication Date
WO2012077968A2 true WO2012077968A2 (en) 2012-06-14
WO2012077968A3 WO2012077968A3 (en) 2012-07-26

Family

ID=46207595

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/009413 WO2012077968A2 (en) 2010-12-09 2011-12-07 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof

Country Status (18)

Country Link
EP (1) EP2648730A4 (zh)
KR (1) KR101414814B1 (zh)
CN (1) CN103249415B (zh)
AR (1) AR084195A1 (zh)
AU (1) AU2011339150B2 (zh)
BR (1) BR112013013415A2 (zh)
CL (1) CL2013001626A1 (zh)
CO (1) CO6721030A2 (zh)
DO (1) DOP2013000115A (zh)
EA (1) EA201390844A1 (zh)
IL (1) IL226449A0 (zh)
MX (1) MX2013005716A (zh)
PE (1) PE20140699A1 (zh)
PH (1) PH12013500980A1 (zh)
SG (1) SG190326A1 (zh)
UA (1) UA108277C2 (zh)
UY (1) UY33772A (zh)
WO (1) WO2012077968A2 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2878301A4 (en) * 2012-07-24 2016-03-23 Zhaoke Pharmaceutical Guangzhou Company Ltd COMBINATION PREPARATION OF LERCANIDIPIN AND ATORVASTATIN
US11382866B2 (en) * 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2663460C2 (ru) * 2013-03-12 2018-08-06 ЭлДжи КЕМ, ЛТД. Комбинированный препарат, содержащий валсартан и розувастатин кальция и способ его изготовления
KR102233986B1 (ko) * 2019-06-25 2021-03-30 경남과학기술대학교 산학협력단 라푸티딘 및 이르소글라딘을 함유하는 고형 약제학적 조성물 및 이의 제조방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198789A1 (en) 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
WO2007001067A2 (en) 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512265A (ja) * 2003-12-01 2007-05-17 ライフサイクル ファーマ アクティーゼルスカブ レルカニジピンを含む医薬組成物
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198789A1 (en) 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
WO2007001067A2 (en) 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Guidance for Industry Fixed Dose Combination and Co-Packaged Drug Products for Treatment of HIV", May 2004, FOOD AND DRUG ADMINISTRATION
S. PUJARI ET AL.: "Fixed-dose combinations for HIV/AIDS, tuberculosis and malaria, Report of a meeting held", 16 December 2003, WORLD HEALTH ORGANISATION, article "Safety and long-term effectiveness of generic fixed-dose formulations of nevirapine-based HAART amongst antiretroviral naive HIV-infected patients in India", pages: 99 - 112
See also references of EP2648730A4

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2878301A4 (en) * 2012-07-24 2016-03-23 Zhaoke Pharmaceutical Guangzhou Company Ltd COMBINATION PREPARATION OF LERCANIDIPIN AND ATORVASTATIN
US11382866B2 (en) * 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
US11819577B2 (en) 2017-07-06 2023-11-21 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril

Also Published As

Publication number Publication date
EA201390844A1 (ru) 2013-11-29
KR20120089787A (ko) 2012-08-13
AU2011339150B2 (en) 2015-09-10
PH12013500980A1 (en) 2013-07-08
CN103249415A (zh) 2013-08-14
UY33772A (es) 2012-07-31
UA108277C2 (ru) 2015-04-10
MX2013005716A (es) 2013-06-12
SG190326A1 (en) 2013-06-28
IL226449A0 (en) 2013-07-31
CO6721030A2 (es) 2013-07-31
DOP2013000115A (es) 2014-07-31
KR101414814B1 (ko) 2014-07-21
AR084195A1 (es) 2013-04-24
BR112013013415A2 (pt) 2019-09-24
WO2012077968A3 (en) 2012-07-26
EP2648730A4 (en) 2014-08-06
AU2011339150A1 (en) 2013-06-06
CN103249415B (zh) 2017-12-12
CL2013001626A1 (es) 2013-10-04
PE20140699A1 (es) 2014-06-13
EP2648730A2 (en) 2013-10-16

Similar Documents

Publication Publication Date Title
AU2007297333B2 (en) Solid dosage form of olmesartan medoxomil and amlodipine
WO2013147462A1 (en) Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
WO2019117502A1 (ko) 모사프리드와 라베프라졸을 함유하는 유핵정 복합제제
WO2018070671A1 (ko) 레날리도마이드의 경구용 정제 조성물
WO2018084627A2 (en) Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
WO2012141385A1 (en) Antihypertensive pharmaceutical composition
WO2017003186A1 (en) Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin
WO2012077968A2 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
WO2018062685A1 (ko) 칸데사르탄 및 암로디핀을 포함하는 단일층으로 이루어진 복합제
US20230018600A1 (en) Controlled release formulations comprising drotaverine or salt thereof
WO2024144207A1 (en) Sustained-release tablet comprising apixaban
WO2021125824A1 (ko) 시벤졸린 또는 이의 염을 포함하는 약학 제형
WO2015147467A1 (en) Pharmaceutical preparation comprising telmisartan and (s)-amlodipine with improved oxidative stability
WO2020017808A1 (ko) 날푸라핀 함유 구강붕해정
EP2236160A2 (en) Modified release dimebolin formulations
WO2013157840A1 (ko) 안정성이 향상된 암로디핀 및 로잘탄을 함유하는 복합제 조성물
WO2021145676A1 (ko) 아토르바스타틴 및 에제티미브를 포함하는 정제
WO2022146007A1 (ko) 에피나코나졸 경구용 조성물
WO2016137266A2 (ko) 에페리손과 펠루비프로펜을 함유하는 약제학적 조성물
WO2019212214A1 (ko) 약학적 제제
WO2019199132A1 (ko) 다양한 용량의 레날리도마이드의 경구용 정제 조성물
EP2269586A1 (en) Pharmaceutical composition comprising desloratadine
WO2013169082A1 (ko) 보센탄 제어방출성 경구제제
WO2017171508A1 (ko) 안정성 및 용출율이 개선된 타다라필 및 탐수로신 함유 캡슐 복합제제
WO2014142521A1 (ko) 발사르탄 및 로수바스타틴 칼슘을 포함하는 복합 제제 및 이의 제조방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11847739

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12013500980

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 226449

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/005716

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: DZP2013000329

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 001346-2013

Country of ref document: PE

ENP Entry into the national phase

Ref document number: 2011339150

Country of ref document: AU

Date of ref document: 20111207

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013001626

Country of ref document: CL

WWE Wipo information: entry into national phase

Ref document number: 2013/06919

Country of ref document: TR

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2011847739

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13130

Country of ref document: GE

Ref document number: 13147794

Country of ref document: CO

Ref document number: 2011847739

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201390844

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: A201307936

Country of ref document: UA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013013415

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013013415

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130529